Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > L2

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Apr 27, 2021 12:48pm

94 Views

Post# 33074934

RE:L2

whisky11 wrote:

Level II Quotes

Orders

Shares

Bid

Ask

Shares

Orders

5

194,000

0.045

0.05

3,498,000

48

79

7,035,000

0.04

0.055

1,997,000

38

30

4,255,000

0.035

0.06

1,262,000

20

18

2,178,000

0.03

0.065

1,176,000

18

13

1,007,000

0.025

0.07

1,595,000

27